Previous 10 | Next 10 |
Shares of Abeona Therapeutics ( NASDAQ: ABEO ) gained 10.4% to $3.62 in Tuesday mid-day trading, extending a recent strong run which has seen the stock post gains in four of its last five sessions . The stock rose 7.9% yesterday after Cantor Fitzgerald listed...
NEW YORK and CLEVELAND, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the last patient has completed their 6-month follow-up visit in Abeona’s pivotal Phase 3 VIITAL™ study of its investigational autologous, engineered cell ther...
Cantor Fitzgerald has a "high conviction" on the Phase 3 readouts Abeona Therapeutics ( NASDAQ: ABEO ), Actinium Pharmaceuticals ( NYSE: ATNM ), and PTC Therapeutics ( NASDAQ: PTCT ) plan to report by the year-end. The announcements can lead to sharp gains ...
NEW YORK and CLEVELAND, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 8:...
NEW YORK and CLEVELAND, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a panel discussion at the Cantor Fitzgerald Cell and Genetic Medicines Conference on Thursday, Septem...
Krystal Bio (KRYS) has performed well in the last two months that I have had it. Its B-VEC looks highly approvable. With Amryt's CRL, the competitive gap has widened in favor of Krystal. Krystal Biotech ( KRYS ) is up hugely since I first covered it earlier this year...
Abeona Therapeutics press release ( NASDAQ: ABEO ): Q2 GAAP EPS of -$2.08. Revenue of $1M. Cash, cash equivalents, restricted cash and short-term investments totaled $26.0 million as of June 30, 2022. Shares +1.68% PM. For further details see: Abeona ...
Disposition of MPS programs allows Abeona to extend runway of current cash into 2Q 2023 Phase 3 VIITAL™ study topline data expected in late-3Q/early-4Q 2022 upon completion of final patient monitoring visit in mid-September Baseline wound characteristics in VI...
InVivo Therapeutics Holdings ( NVIV ) +106% . GreenLight Biosciences ( GRNA ) +94% . NanoViricides ( NNVC ) +48% stock skyrockets 50% on start of drug development program for monkeypox. Exicure ( XCUR ) +39% . Global Blood Therapeuti...
Abeona Therapeutics ( NASDAQ: ABEO ) received Nasdaq notification informing it has regained compliance with the minimum bid price requirement. The requirement was met on July 18, 2022. For further details see: Abeona therapeutics regains compliance with Nasdaq mi...
News, Short Squeeze, Breakout and More Instantly...
Abeona Therapeutics Inc. Company Name:
ABEO Stock Symbol:
NASDAQ Market:
Abeona Therapeutics Inc. Website:
CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, today announced ...
CLEVELAND, July 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona’s Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., and Chief Commercial Officer, Madhav Vasanthavada, Ph.D., M.B.A., will participate in a virtual fireside chat at the Sti...
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ABEO on July 3, 2024 06:07AM ET. ABEO was trading at $4.12 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...